INNOVIVA, INC. Noncontrolling Interest, Increase from Subsidiary Equity Issuance
INNOVIVA, INC. (INVA) reported Noncontrolling Interest, Increase from Subsidiary Equity Issuance of $8.00 thousand for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-07-29.
Discontinued › Shareholders' Equity
us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance · last filed 2021-07-29
- INNOVIVA, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2021-06-30 was $8.00K, a 97.71% decline year-over-year.
- INNOVIVA, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2021-03-31 was $8.00K.
- INNOVIVA, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2020-09-30 was $8.00K.
- INNOVIVA, INC. noncontrolling interest, increase from subsidiary equity issuance for the quarter ending 2020-06-30 was $350.00K.
- INNOVIVA, INC. noncontrolling interest, increase from subsidiary equity issuance for fiscal 2020 was $366.00K.
- INNOVIVA, INC. noncontrolling interest, increase from subsidiary equity issuance for fiscal 2017 was $23.00K.
| Period end | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 3 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 6 month | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 12 month |
|---|---|---|---|
| 2021-06-30 | $8.00K 10-Q · filed 2021-07-29 | $16.00K derived: sum of 2 quarters · filed 2021-07-29 | |
| 2021-03-31 | $8.00K 10-Q · filed 2021-07-29 | ||
| 2020-12-31 | $366.00K 10-K · filed 2021-02-25 | ||
| 2020-09-30 | $8.00K 10-Q · filed 2020-10-28 | $358.00K derived: sum of 2 quarters · filed 2021-07-29 | |
| 2020-06-30 | $350.00K 10-Q · filed 2021-07-29 | ||
| 2017-12-31 | $23.00K 10-K · filed 2020-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |